ABSTRACT

Introduction: Influenza can be a significant public health problem. Nevertheless, it is preventable through vaccination. Concerning the pediatric population, the recommendation of influenza vaccination is under-represented in many European countries. The aim of this systematic review is to evaluate the cost-effectiveness of universal childhood vaccination against influenza in Europe.

Areas covered: We conducted a systematic review of original article assessing the cost-effectiveness of influenza vaccination by searching PubMed, Embase and Scopus databases for studies in English, starting from January 1^st, 2010 up to October 21^st, 2020.

Expert opinion: Our literature review showed that all studies identified highlight that pediatric vaccinations using a live vaccine, especially in the quadrivalent formulation, are cost-effective compared to current vaccinations (elderly and at-risk groups) with TIV or no vaccination. A significant contribution to this positive economic profile is due to the indirect protection. Already many clinical data report the relevant direct and indirect impact of vaccination against influenza for younger subjects. The recent studies collected in this review showed also that the pediatric vaccination is also cost-effective. Therefore, decision-makers should now consider this new favorable evidence.

摘要

简介: 流感可能是一个重大的公共卫生问题。然而，它是可以通过接种疫苗来预防的。关于儿科人群，许多欧洲国家对流感疫苗接种的建议不足。本系统评价的目的是评估欧洲儿童普遍接种流感疫苗的成本效益。

涵盖的领域：从2010 年1 月 1^日至2020 年10 月 21^日，我们通过在 PubMed、Embase 和 Scopus 数据库中搜索英文研究，对评估流感疫苗接种成本效益的原始文章进行了系统评价。

专家意见：我们的文献综述表明，所有确定的研究都强调，与当前使用 TIV 或不接种疫苗的疫苗接种（老年人和高危人群）相比，使用活疫苗（尤其是四价制剂）的儿科疫苗接种具有成本效益。间接保护对这种积极的经济状况做出了重大贡献。许多临床数据已经报告了接种流感疫苗对年轻受试者的相关直接和间接影响。本综述中收集的最近研究还表明，儿科疫苗接种也具有成本效益。因此，决策者现在应该考虑这一新的有利证据。